CTLA4 and melanoma: Moreover, a marked increase in class-switched memory B cells, plasmablasts and CD21low B cells was observed after the first cycle of combined administration of anti-PD-1 and anti-CTLA-4 mAbs in melanoma patients (85) (Figure 2).